Norway Medical and Diagnostic Laboratory Service Market Analysis Sample Report

Norway Medical and
Diagnostic
Laboratory Service
Market Analysis
A sample report on
www.insights10.com
Includes Market Size, Market Segmented by Types
and Key Competitors (Data forecasts from 2022 – 2030F)

This report presents a strategic analysis of the Norway Medical and
Diagnostic Laboratory Service Market Analysis and a forecast for
its development in the medium and long term. It provides a comprehensive
overview of the market value, dynamics, segmentation, types of clinical
diagnostics, point-of-care testing, main players, growth and demand
drivers, challenges & future outlook, etc. This is one of the most
comprehensive reports about the Norway Medical and Diagnostic
Laboratory Service Market Analysis, and offers unmatched value,
accuracy, and expert insights

3
A Sample Report on Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Healthcare Diagnostics Overview 12-25
1.1. Overview
1.2. Norway Overview
1.3. Economic Overview: Norway
1.4. Healthcare Diagnostics Market in Norway
1.5. Healthcare Services Market in Norway
1.6. Healthcare Scenario in Norway
1.7. Health Insurance Coverage: Norway
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting
2.1 Market size and forecasts (Excel and Methodology) 26-33

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. By Test
2.2.2. By Product
2.2.3. By End User
3. Market Dynamics 34-38
3.1. Market Growth Drivers
3.1.1. Norway Medical and Diagnostic Laboratory Service Market Analysis Driver 1
3.2. Market Restraints
3.2.1. Norway Medical and Diagnostic Laboratory Service Market Analysis Restraint 1

6
Table of Content
CONTENT PG. NO.
4. Competitive Landscape 39-49
4.1. Major Market Share
4.2. Key Company Profile
4.2.1. Vestre Viken HF
4.2.1.1. Overview
4.2.1.2. Product Applications & Services
4.2.1.3. Recent Developments
4.2.1.4. Partnerships Ecosystem
4.2.1.5. Financials (Based on Availability)
4.2.2. Fürst Medical Laboratory
4.2.2.1. Overview

7
Table of Content
CONTENT PG. NO.
4.2.3. Sykehusapotekene
4.2.3.1. Overview
4.2.4. Norgesplaster
4.2.4.1. Overview

8
Table of Content
CONTENT PG. NO.
4.2.5. Unilabs
4.2.5.1. Overview
4.2.6. SYNLAB Norge
4.2.6.1. Overview

9
Table of Content
CONTENT PG. NO.
4.2.7. Aleris
4.2.7.1. Overview
4.2.8. Quantum Diagnostics Sdn Bhd
4.2.8.1. Overview

10
Table of Content
CONTENT PG. NO.
4.2.9. Oslo University Hospital
4.2.9.1. Overview
4.2.10. Helse Bergen
4.2.10.1. Overview

11
Table of Content
CONTENT PG. NO.
5. Reimbursement Scenario 50-57
5.1. Reimbursement Regulation
5.2. Reimbursement Process for Diagnosis of Diseases
5.3. Reimbursement Process for Treatment of Diseases
5.4. Reimbursement Process – Medicare
5.5. Reimbursement Process - Medicaid
6. Methodology & Scope 58-63

Norway Medical and Diagnostic Laboratory Service Market Analysis
1. Healthcare Diagnostics Overview

13
1.1 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the World
Scope of Healthcare Diagnostics ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
165.58 Bn
Global diagnostic market
stood at USD 165.58 Bn in
2021
3.24%
Diagnostics segment in
globe is projected to grow
by 3.24% (2023-2027)
resulting in a market
volume of $348.75 Bn in
2030
68.96%
non-communicable
diseases are responsible
for 74% of all fatalities in
World

14
1.1 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the World
(continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027
Asia
-Fastest CAGR
Africa
~Market Size of $xx
Egypt Market
~$xx Market
Illustrative

15
1.2 Norway Overview
5.54 Mn
Is the population of
Norway, in 2023
34.68
Is the median age
in Norway, in 2022
489.68 Bn
Is the Gross
Domestic Product
(GDP) in Norway in
2023
$89,154.28
per capita was the
amount of national
health expenditures in
2022
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest

16
1.3 Economic Overview: Norway
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Norway, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Norway, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

17
1.4 Statistics at a Glance: The Scenario of Healthcare Diagnostics in the
Norway
Scope of Healthcare Diagnostics ▪ Please be aware that this sample report is
report
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
interest
1258.65 Mn
Norway Medical and
diagnostic market stood at
USD 1011.24 Million in 2021
4.58%
Diagnostics segment in
Norway is projected
to grow by 4.58% (2023-
2027) resulting in a market
volume of US$1235.58 Mn
in 2027
$3.2 billion
Norway’s healthcare
expenditures are expected to
double to $3.2 billion by
2028
68.59%
non-communicable
diseases are responsible
for 68.59% of all fatalities
in Norway

18
1.5 Healthcare Services in Norway
xx xx xx xx xx xx xx xx xx
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Norway Healthcare Services Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Healthcare Services market in Norway, which includes the market size, current
trends and other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative

19
1.6 Healthcare Scenario in Norway
Cancer Drug Development Process: The process of developing a cancer drug is complex and involves many stages, from preclinical research
to clinical trials to regulatory approval. Here is a simplified diagram of the cancer drug development process:
o Preclinical Research: Researchers identify potential drug candidates and test them in the lab
o Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans
o Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating cancer
o Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and
effectiveness
o Regulatory Approval: The drug is reviewed by regulatory agencies such as the FDA and approved for use in the US market
Fast Track
▪ Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat
serious conditions and fill an unmet medical need
Breakthrough
Therapy
▪ A process designed to expedite the development and review of drugs which may demonstrate substantial
improvement over available therapy
Accelerated
Approval
▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved
based on a surrogate endpoint
Priority Review ▪ A Priority Review designation means FDA’s goal is to take action on an application within 6 months
FDA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and
effectiveness. Here are four of these approaches:
Illustrative

20
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

21
1.7 Health Insurance Coverage: Norway
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Medicaid
Medicare
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed by Medicaid (18.9%), Medicare (18.4%), direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care
(1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
Medicare 58,541 60,226 0.5
Medicaid 58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative

22
1.8 Budget of Norway Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Medicaid $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Medicare 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Medicaid 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Medicare spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE
▪ Medicaid spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

23
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

24
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Oracle acquisition of
Cerner
Acquisition $28.3 Bn June, 2022
▪ Oracle’s acquisition of Cerner is big tech’s latest foray into the
healthcare system, promising better outcomes
▪ Oracle acquire Cerner through an all-cash tender offer for $95.00
per share, or approximately $28.3 Bn in equity value
▪ Cerner is a leading provider of digital information systems used
within hospitals and health systems to enable medical
professionals to deliver better healthcare to individual patients
and communities
GSK acquisition of
BELLUS Health
Acquisition $2 Bn April 2023
▪ GSK has acquire BELLUS for US$14.75 per share of common
stock in cash representing an approximate total equity value of
US$2.0 billion
▪ BELLUS is a late-stage biopharmaceutical company working to
better the lives of patients suffering from persistent cough
▪ Acquisition further strengthens specialty medicines and
respiratory pipeline with camlipixant, a highly selective P2X3
antagonist and potential best-in-class treatment for refractory
chronic cough
Latest Deals In Norway
Illustrative

25
1.9 Mergers and Acquisitions (continued)
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Norway
Illustrative

2. Market Size and Forecasting

27
2.1 Market size and forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Norway Medical and Diagnostic Laboratory Service Market Forecast,
2022-2030 (in $Bn)
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the overall Healthcare
Insurance market in Norway, which
includes the market size, current trends
and other details related to the topic
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Norway Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of US Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Norway Market Size (Bn
$)
61 74 84 87 91 95 99 106
Illustrative

28
2.2 Snapshot of Norway Medical & Diagnostics Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Norway Medical and Diagnostic Laboratory
Service Market Analysis
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
By Test
Lipid Panel
Liver Panel
Infectious Disease Testing
Renal Panel
By Product
Instruments
Reagents
Other Products
By End User
Hospital Laboratories
Diagnostics Laboratory
Point of care Testing

29
Norway Medical and Diagnostic Laboratory Service Market Share,
By Test (2022)
Lipid Panel
Liver Panel
Infectious
Disease Testing
Renal Panel
▪ Lipid Panel in Norway is a significant
component of the overall cancer
treatment market
▪ It has the maximum market share in
Norway market with approximately xx%
final report
2.2.1 Market Segmentation: By Test
Illustrative

30
Norway Medical and Diagnostic Laboratory Service Market Share,
By Product (2022)
Intruments
Reagents
Other Products
2.2.2 Market Segmentation: By Product
▪ Instrument in Norway is a significant
component of the overall cancer market
▪ It has the maximum market share in
Norway market with approximately xx%
final report
Illustrative

31
Norway Medical and Diagnostic Market Share, By End User (2022)
Hospital
Laboratories
Diagnostics
Laboratories
Point of Care
Testing
2.2.3 Market Segmentation: By End User
▪ Hospitals have the maximum market
share in Norway market with
approximately xx%
final report
Illustrative

3. Market Dynamics

33
3.1 Market growth drivers
▪ Norway has a robust healthcare system with a high level of public
healthcare expenditure.
▪ The government's focus on healthcare infrastructure development,
increasing healthcare budgets, and investment in advanced diagnostic
technologies drive the growth of the medical and diagnostic laboratory
services market.
▪ Technological advancements in diagnostic tools and techniques have
revolutionized medical testing.
▪ Norway has been at the forefront of adopting innovative diagnostic
technologies, such as molecular diagnostics, genetic testing, and
advanced imaging techniques.
▪ The availability of state-of-the-art diagnostic equipment and techniques
drives market growth.
2010 2022 2030
3.1.1 Norway’s per capita health expenditure is also much higher than in most countries – over $5268.54 in 2021.
Public sources account for 85.5% of current health expenditure, which is the highest share in Europe.
Illustrative
Incidence of Cancer in Norway

34
3.1 Market growth drivers (continued)
3.1.2 The mean age at birth increased between 2015 and 2023 in all of Norway, for both genders. The biggest gains
were made in Oslo, where the life expectancy at birth rose from 71.9 years (71.4-57.2) in 2015 to 81.3 years (80.0-82.7)
in 2023 for men and from 79.0 years (71.4-0) in 2015.
▪ Norway, like many developed countries, has an aging
population.
▪ The elderly population tends to require more medical testing
and diagnostic services to manage age-related conditions
and chronic diseases.
▪ The aging demographic contributes to the growth of the
medical and diagnostic laboratory services market.
2010 2022 2030
Illustrative

35
3.1 Market growth drivers (continued)
3.1.3 Over the past 50 years, cardiovascular disease mortality in Norway has decreased dramatically, and the
majority of deaths now occur in those over the age of 80. Every year, 32,000 new cases of cancer are discovered, and
over 70,000 persons with cardiovascular disease are treated in hospitals and outpatient clinics.
Norway is facing a rising burden of chronic diseases such as
cardiovascular diseases, diabetes, and cancer.
The need for accurate and timely diagnosis, disease monitoring, and
treatment planning fuels the demand for medical and diagnostic laboratory
services.
Illustrative
United States
Japan
Germany
South Korea
China
United Kingdom
France
Canada
Australia
Israel
Switzerland
Singapore
Sweden
Netherlands
Italy
Spain
Belgium
Denmark
Austria
Norway
Top countries that are leveraging technology
in their fight against cancer

36
3.2 Market restraints
3.2.1 In 2022, the
average cost of a
diagnostic services in
Norway was over
$682.59
Affordability can be a significant
restraint for certain segments of the
population, particularly those with
lower income levels or inadequate
health insurance coverage. The cost
of healthcare diagnostics, including
laboratory tests, imaging
procedures, and specialized tests,
may pose financial constraints for
individuals, impacting their ability to
access and undergo necessary
diagnostic services
3.2.2 Average cost of
developing a diagnostic
technique that is ultimately
approved by the regulatory
authority in Norway is over
$1856.25
Regulatory processes and
compliance requirements can pose
challenges for companies operating
in the healthcare diagnostics market.
The approval and registration of
diagnostic products, technologies,
and services by regulatory
authorities can be time-consuming
and costly. Compliance with quality
standards, data privacy regulations,
and other regulatory aspects adds
complexity to the market
3.2.3 In 2020, the average cost of
a laboratories services in Norway
was over $785.68
The healthcare Laboratories market
in Norway is characterized by the
presence of multiple stakeholders,
including private laboratories,
diagnostic centers, hospitals, and
government agencies. This
fragmentation can lead to variations
in service quality, pricing, and
standards across different providers,
which may impact the overall market
consistency and create challenges in
standardization and coordination
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative

4. Competitive Landscape

38
4.1 Major Market Share
XX
Other
interest market
Revenue of Major players in Norway Medical and
Diagnostic Laboratory Service Market ($ Mn)
Illustrative

39
4.2 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Vestre Viken HF
3 Sykehusapotekene
5 Unilabs
7 Aleris
9 Oslo University Hospital
2 Fürst Medical Laboratory
4 Norgesplaster
6 SYNLAB Norge
8 Quantum Diagnostics Sdn Bhd
Helse Bergen
10
Key Note:

40
4.2.1 Vestre Viken HF
Founded in: 30 March 2009
HQ: Drammen, Norway
Type: Private
Revenue: $ 1.489 Bn
Website: https://vestreviken.no/
▪ One of Norway's biggest healthcare organisations is Vestre Viken
HF. In the Vestre Viken region, which comprises the counties of
Buskerud, Drammen, Kongsberg, Ringerike, and Hurum, it is a
health trust charged with delivering specialised healthcare
services.
▪ Several hospitals and healthcare institutions in the area are run
by Vestre Viken HF. These facilities offer a broad range of
healthcare services, such as emergency, surgical, and
specialised care for patients with different medical specialties.
Solutions offered by Adventa
Berhad
➢ Diagnostics
➢ Pharmaceuticals
➢ Medical Services
➢ Clinical Trials
➢ Surgical Services
Recent Activity / Press Coverage
In 2023, Vestre Viken HF business model is to provide its Laboratories and Radiology services to public and Trust hospitals. Patients will
be allowed to lease and take the machine home for a customised self-treatment programme at the cost of about $698.587 a month
In February 2021, Vestre Viken HF announced plans to invest over $94.68 Mn in a new hospital in Drammen, Norway. The new hospital will
be a state-of-the-art facility with 135,000 square meters of floor space and 350 patient rooms, and it is expected to be completed by 2029.
In 2021, Vestre Viken HF signed an agreement with GE Healthcare to implement a new digital pathology system across its hospitals. The
system will allow for more accurate and efficient diagnoses, and it is expected to improve patient outcomes and reduce costs.

41
4.2.1 Vestre Viken HF (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
One of the largest pharmaceutical
distributors in the United States, McKesson
has been a long-standing distribution
partner for Roche
Cardinal Health is a Fortune 500 healthcare
services company that provides
pharmaceutical distribution services to
Roche
It is one of the largest drugstore chains in
the United States and Europe, and its
extensive network of retail locations and
distribution centers make it an important
distribution partner for Roche
A leading healthcare services provider in
Asia, Zuellig Pharma is a distribution
partner for Roche in several Asian countries
One of the largest pharmaceutical
wholesalers in Europe, PHOENIX Group
distributes Roche's products in several
European countries
Roche has been working with SAP, a
leading software company, to develop digital
solutions for its healthcare products
A leading Swiss biotechnology company,
Lonza provides Roche with contract
manufacturing services for the production of
its biologics and pharmaceuticals
Roche has a strategic partnership with
Microsoft to leverage its cloud computing
and AI technologies in the development of
new healthcare products
Thermo Fisher Scientific is a leading
provider of analytical instruments, reagents,
and laboratory services
GE Healthcare provides Roche with
advanced medical imaging and diagnostics
technologies, including CT scanners and
MRI machines
Illustrative

42
Company Name Type
Amount /
Duration
Year Key Pointers
Lilly
Collaboration - March, 2023
▪ Roche and Lilly will collaborate on the development of Roche
Diagnostics’ Elecsys Amyloid Plasma Panel
▪ Elecsys Amyloid Plasma Panel has demonstrated clinical
performance and is currently undergoing additional investigation
to ensure clinical validation
▪ Once approved, could help healthcare professionals to streamline
the journey to diagnosis for more patients
GenMark Diagnostics
Merger $1.8 Bn March 2021
▪ Roche to acquire GenMark Diagnostics for US$ 24.05 per share
with the expectation to close in the 2nd quarter of 2021
▪ GenMark provides molecular diagnostic tests that are designed to
detect multiple pathogens from a single patient sample
▪ GenMark’s ePlex platform delivers rapid and actionable results so
clinicians can determine the cause of infection and the most
effective treatment, potentially saving lives and alleviating the
healthcare burden
Latest Deals - Mergers and Acquisitions
Illustrative

43
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ According to Roche's 2020 financial report,
the company had sales of CHF 58.3 Bn
(Swiss Francs) in 2020
▪ This is equivalent to approximately $63.3
Bn USD, based on exchange rates at the
end of 2020
▪ Company's Pharmaceuticals Division
generated sales of CHF 49.9 Bn in 2020,
while the Diagnostics Division generated
sales of CHF 8.4 Bn
▪ Revenue generated by Roche in 2020
reflects the company's continued growth
and success in the healthcare industry
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

44
4.2.2 Company 2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

45
4.2.2 Company 2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

46
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

47
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
▪ Please be aware that this sample report is
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

49
5.1 Reimbursement Regulation
The reimbursement scenario in the US cancer market is complex and can vary
depending on the specific treatment, setting of care, and insurance coverage.
Here are some key points to consider:
▪ Medicare:
o Medicare is a federal health insurance program for people aged 65 and
older, as well as people with certain disabilities or health conditions
o Medicare covers many cancer treatments, including chemotherapy,
radiation therapy, and some immunotherapies
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Medicaid:
o Medicaid is a joint federal-state program that provides health insurance
for people with low incomes
o Medicaid coverage for cancer treatments can vary by state, and may be
subject to limits on the amount and type of treatment covered
▪ Private Insurance:
o Private insurance coverage for cancer treatments can also vary widely
depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Medicare and Medicaid together provide
health insurance coverage for more than
4 in 10 Americans
Medicare
17%
Medicaid
and CHIP
21%
Employer-Sponsored
49%
Other Private
3%
Other Public
1%
Uninsured
9%
Health Insurance Coverage, 2022
Illustrative

50
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to cancer treatments by requiring insurers to cover
certain preventive services, including cancer screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as cancer
▪ Reimbursement for New Treatments:
o Reimbursement for new cancer treatments can be a complex and lengthy process, as insurers and government programs
often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focusing on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

51
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

52
5.2 Reimbursement Process for Diagnosis of Diseases
The reimbursement process in the US healthcare system can be complex and can vary depending on the type of healthcare service,
the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative

53
5.3 Reimbursement Process for Treatment of Diseases
The reimbursement process in the US healthcare system can be complex
and can vary depending on the type of healthcare service, the healthcare
provider, and the insurance coverage. Here are the general steps involved
in the reimbursement process:
▪ Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪ Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪ Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪ Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
FDA
Private Payers Public Payers
Health Technology Assessment
Payment
Coverage
Coding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 3
2
Illustrative

54
5.4 Reimbursement Process - Medicare
Medicare
Population Covered
▪ 100% population is covered under this scheme
▪ Citizen’s contribute to this scheme which then earns an interest. There is Basic Healthcare Sum (BHS) cap which limits the maximum contribution to an
individuals Medicare account
Provider Restrictions/
Selection
Services can be claimed from Medicare-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicare and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicare account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicare account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicare up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

55
5.5 Reimbursement Process - Medicaid
Medicaid
Population Covered
▪ 38% population is covered under this scheme
▪ Medicare covers individuals who are aged 65 and older, as well as those with certain disabilities or end-stage renal disease
Provider Restrictions/
Selection
Services can be claimed from Medicaid-approved institutions only (14 public hospitals, 10 private hospitals, 7 public community centers, 1 private community
center and over 100 surgery centers, dialysis centers, colonoscopy centers and screening centers)
Services Covered
▪ Medicines under SDL and MAF Plus can be bought from the money saved in this account
▪ Money can be also be claimed for antiretroviral drugs for HIV, Desferrioxamine drug for treatment of thalassemia and immuno-suppressant drugs for organ
transplant
▪ Money from this account can be used to pay Medishield premiums and Integrated Shield Plan premiums, subject to withdrawal limits
▪ Patients above 65 years of age can claim under Flexi-Medicaid and further reduce their out-of-pocket expenses by using up to $200 per patient per year from
their Medicaid account
▪ Excluded: Traditional drugs such as Herbal and Ayurveda cannot be claimed from Medicaid account; Drugs used for cosmetic purposes such as slimming pills
and hair loss pills cannot be claimed from this account
Level of Coverage/ Assurance
▪ Approved chronic conditions and vaccinations, health screenings as outpatient treatments can be paid with Medicaid up to $500 per account per year, however
a cash copayment of 15% is applicable
▪ Inpatient hospitalization, up to $450 per day + surgical limits according to Table of Surgical Procedures
▪ Approved day surgeries up to $300 per day + surgical limits according to Table of Surgical Procedures
▪ Outpatient scans/ diagnostics for cancer up to $600 per year per patient, and up to $300 for other medical conditions
▪ Chemotherapy (includes analgesic medication and suppressive treatments such as neuroendocrine and nuclear medicine treatments) up to $1,200 per month
per patient
▪ Renal dialysis up to $450 per patient per month
▪ Other treatments are also approved with various sub-limits for withdrawal
Mechanism of Coverage
▪ DRG with Activity Based Funding for public providers
▪ Block funding with DRG for providers not covered under ABF
Financial Feasibility ▪ The Basic Healthcare sum has been increased by more than 4.4% in 2017 on account of increasing costs of healthcare. This is an individual account
Illustrative

Norway Medical and Diagnostic Laboratory Service Market Analysis Analysis
6. Methodology & Scope

Research Methodology
▪ Insights 10’s research methodology delves deeper into the market, covering the macro and micro aspects of the industry. We identify the
key growth drivers, opportunities, and restraints that might promote or hinder the future industry growth along with an expansive
overview of the competitive landscape to help our clients make informed strategic decisions
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conduct extensive data mining, referring to verified data sources such as independent studies, government
and regulatory published material, technical journals, trade magazines, and paid data sources
▪ For forecasting, the following parameters are considered:
❑ Market drivers and restraints along with their current and expected impacts
❑ Technological scenario and expected developments
❑ End use industry trends and dynamics
❑ Trends in the consumer behavior
❑ Regulatory scenario and expected developments
❑ Current capacity and expected capacity additions up to 2030
▪ We assign weights to these parameters and quantify their market impacts using the weighted average analysis to derive the expected
market growth rate
▪ We appoint data triangulation strategies to explore different areas of the market. Our qualitative and quantitative assessments are time-
sensitive, reflecting the most recent value and volume of the market across regions
▪ All our estimates and forecasts are verified through exhaustive primary research with the Key Industry Participants (KIPs)
▪ Currency used in the report is the US dollar (USD), with the market size indicated in USD million/billion (Mn/Bn)

Analysis Methodology
Our Analysis Methodology involves three critical stages:
Market Trends
Market Sizing &
Analysis
Data Triangulation &
Validation
Analysis &
Interpretation
Insights
Presentation &
Reporting
Market Data Analysis
& Statistical Model
Interpretation &
Presentation
Secondary
Research
Proprietary
Database
Data
Collection
Primary
Research

Data Triangulation & Data Validation
Bottom Up Approach
Summarization of revenue
generated from companies
to arrive at total market size
Revenue generated by products &
services offered by companies
Validation from
Primary Interview
Final
Market
Size
Top Down Approach
Final Market size break up to
rest of segmentation
Arriving at market size
of each segment
Validation from
Primary Interview
Final
Summary

Key Benefits for Stakeholders from this Report
Study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent
investment pockets
Our tools provides stakeholders with a cohesive understanding of the industry outlook, considering the qualitative and
quantitative industry variables
Comprehensive analysis of factors that drive and restrict the market growth is provided
Comprehensive quantitative analysis of the industry from 2022 to 2030F is provided to enable the stakeholders to capitalize on
the prevailing market opportunities
Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
Our rigorous data collection, thorough statistical analysis and specialist assessments ensure that our clientele has a greater
understanding of the industry space, supply chain, price fluctuations, competitive landscape, and other vital factors

2022
2023-
2030
Report Attribute
Quantitative Units
Report Coverage
Customized Report
Pricing and purchase
options
Revenue in USD Million/Billion (Mn/Bn)
Market Overview, Revenue Forecast, Market
Segmentation, Growth Factors and Trends,
Company Profiles, Competitive Landscape,
Regulatory Landscape, Future Opportunities
Report Customization (3 to 5 working days)
with purchase. We will provide you with data
that is currently not a part of our scope as a
part of customization
Avail customized purchase options to meet
your exact research needs
Details
Time Frame
Base Year for
Estimation
Forecast
Period

Insights10 is a healthcare focused market
research firm founded with an aim of being an
insights driven company in the data driven world
and delivering actionable insights that can drive
decision and strategy making process for
businesses
www.insights10.com
Lifesciences Market
Research Reports you
can trust

www.insights10.com
A large database of over 30,000 syndicated
market research reports in Healthcare Services
and healthcare sector at global, regional as well as
country level. We also provide customized
research reports tailor made to suit your needs
Get actionable insights to
take informed business
decisions

Our qualitative, acute, and result-oriented market
research reports provide a comprehensive
understanding of the business scenario and the
latest trends related to the life sciences market
Elevate your business plans
with in-depth market analysis
and industry intelligence
www.insights10.com

Whether you are looking to expand into new
areas, develop new products, or take advantage
of new opportunities we have reports to help you
accelerate and improve your plans by identifying
unique growth prospects.
Gain a competitive edge with
Insights10's customized
healthcare research solutions
www.insights10.com

Healthcare
Services
Clinical
Trials
OTC &
Nutraceuticals
Healthcare Services
(Diseases & Drugs)
Digital
Health
Medical
Devices
across various categories
Market Research Reports

FEATURED REPORTS FREE SAMPLE REPORTS
TRENDING TOPICS

1200+
Reports
Published
Annually
30000+
Life science
Market Research
Reports
22000+
Country
Specific
Reports
2000+
Rare & orphan
Disease
Reports
What makes us different?

Market Overview
Growth Drivers &
Growth Restraints
Market Segmentation
Market Share Factors Driving Future Growth
Reimbursement Scenario
Policy & Regulatory
Landscape
Key Company Profiles
Epidemiology &
Disease type
Competitive Landscape
insights on
which our
reports are
based
1
2
3
4
5
6
10
9
8
7
Table of Contents

Subscription
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database
Service
Primary
Research
Customized
Reports
Market Research
Reports
Our Services

Research Projects Done
Over the years, we have developed an in-depth experience of executing
market analysis at global, regional & country specific level in life sciences.
Our team has
conducted market
research across 62+
global markets in
America, Europe,
Middle East, Africa and
Asia Pacific regions

Our Research Process
01 03
02 04 05
Identification of
Data
Collection of
Data
Market
Dynamics
Collaboration
of Data
Verification &
Analysis

Statistical Databases
Data
Sources
We have access to multiple highly
reliable free and subscription data
sources. We have many years of
experience to understand which
sources are more dependable for what
and which to prefer for the reliable and
latest information.
Company Websites/Annual Reports
Trade Publications
Online Databases
Published Research Reports
Whitepapers
Press Releases of Key Market Players

What kind of data is presented
in our reports?
Our reports present data, which is:
The report is
prepared using a
proven methodology
and insightful
research
Reliable
The data is prepared
by a team of highly
qualified &
experienced research
analysts & vetted by
our local associates
Expert-verified
Allowing you to
confidently make
smarter business
and strategic
decisions
Real
Covers everything
you would need to
know about the
market including
market size,
competitive analysis
& much more
Comprehensive
You do not have to
be a market expert
to understand what
really is happening
on the market and
how it works
Easy to read

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market.
We at Insights10 are building the future of market
research and are committed to providing our clients with
the right intelligence and insights to make business
decisions quickly and efficiently.
Insighs10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working
with some of the best organizations in the world,
generating insights that provides substantial competitive
advantage.”
Dr. Purav Gandhi
Founder & CEO

Purav is a physician and an entrepreneur
with 12+ years of experience in Healthcare
& Life Sciences industry spanning across
strategy, market access, health informatics
and RWE, digital health, analytics and data
science. Purav studied medicine from
Gujarat University and also completed his
MBA from IIM-Kozhikode. Purav started
his career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of experience
in management consulting in the
Life Sciences sector, and has
worked with diverse multinational
firms in the US, India, Middle East
and APAC regions. His primary
area of interest is Customer and
Market Strategy, Market Access,
and Digital Health with special
focus on emerging markets like
Africa, Middle East and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Leadership Team
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research & marketing
professional with a progressive
experience of over 20 years in Life
Sciences, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across diff.
markets (America, Europe, Africa, APAC
and Middle East). Her areas of expertise
include: Indentifying emerging trends in life
sciences industry, Competitor landscape
assessment, Disease opportunity
assessments etc. She is a pro in secondary
and primary research with a deep domain
expertise in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager

Web: www.insights10.com
Email: insights@insights10.com
Call: (+91) 931 639 7935
WhatsApp: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

www.insights10.com
Thank you
We truly appreciate your business and
look forward to serving you.

Norway Medical and Diagnostic Laboratory Service Market Analysis Sample Report

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Ähnlich wie Norway Medical and Diagnostic Laboratory Service Market Analysis Sample Report

Ähnlich wie Norway Medical and Diagnostic Laboratory Service Market Analysis Sample Report (20)

Mehr von Insights10

Mehr von Insights10 (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Norway Medical and Diagnostic Laboratory Service Market Analysis Sample Report